ZA201406145B - Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use - Google Patents
Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of useInfo
- Publication number
- ZA201406145B ZA201406145B ZA2014/06145A ZA201406145A ZA201406145B ZA 201406145 B ZA201406145 B ZA 201406145B ZA 2014/06145 A ZA2014/06145 A ZA 2014/06145A ZA 201406145 A ZA201406145 A ZA 201406145A ZA 201406145 B ZA201406145 B ZA 201406145B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- pharmaceutical compositions
- fumarate compounds
- morpholinoalkyl
- morpholinoalkyl fumarate
- Prior art date
Links
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261595835P | 2012-02-07 | 2012-02-07 | |
| PCT/US2013/025118 WO2013119791A1 (en) | 2012-02-07 | 2013-02-07 | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201406145B true ZA201406145B (en) | 2016-06-29 |
Family
ID=47720772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/06145A ZA201406145B (en) | 2012-02-07 | 2014-08-21 | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8952006B2 (enExample) |
| EP (1) | EP2812319A1 (enExample) |
| JP (1) | JP5918395B2 (enExample) |
| KR (1) | KR20140129136A (enExample) |
| CN (1) | CN104169261A (enExample) |
| AU (1) | AU2013203335B2 (enExample) |
| BR (1) | BR112014019480A8 (enExample) |
| CA (1) | CA2864040A1 (enExample) |
| IL (1) | IL233941A0 (enExample) |
| MX (1) | MX2014009511A (enExample) |
| NZ (1) | NZ629728A (enExample) |
| RU (1) | RU2014136394A (enExample) |
| TW (1) | TWI486339B (enExample) |
| WO (1) | WO2013119791A1 (enExample) |
| ZA (1) | ZA201406145B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2554347C2 (ru) | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
| EP2854795A1 (en) * | 2012-05-30 | 2015-04-08 | XenoPort, Inc. | Treatment of multiple sclerosis and psoriasis using prodrugs of methyl hydrogen fumarate |
| US20140057918A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
| US20140056973A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| US20140179779A1 (en) * | 2012-12-21 | 2014-06-26 | Biogen Idec Ma Inc. | Deuterium Substituted Fumarate Derivatives |
| DK2970101T4 (da) | 2013-03-14 | 2025-11-17 | Alkermes Pharma Ireland Ltd | Pro-drugs af fumarater og deres anvendelse i behandling af forskellige sygdomme |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
| US20160214948A1 (en) * | 2013-09-27 | 2016-07-28 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (mmf) |
| US9663480B2 (en) * | 2013-12-05 | 2017-05-30 | Ratiopharm Gmbh | BIS-MMF derivatives |
| EP3110793B1 (en) * | 2014-02-24 | 2019-08-21 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| ES2718548T3 (es) | 2014-03-21 | 2019-07-02 | Univ Paris Val De Marne | Híbridos de molécula de liberación de CO-fumarato, su utilización en el tratamiento de enfermedades inflamatorias o cardiovasculares y su procedimiento de preparación |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
| US10170537B2 (en) | 2014-12-23 | 2019-01-01 | International Business Machines Corporation | Capacitor structure compatible with nanowire CMOS |
| US9630934B2 (en) * | 2015-02-08 | 2017-04-25 | Mark Quang Nguyen | Fumarate compounds, pharmaceutical compositions thereof, and methods of use |
| AU2016268340B2 (en) | 2015-05-28 | 2021-07-08 | Baylor College Of Medicine | Benefits of supplementation with N-acetylcysteine and glycine to improve glutathione levels |
| WO2019042301A1 (zh) * | 2017-08-29 | 2019-03-07 | 浙江海正药业股份有限公司 | (E)-α,β-不饱和酰胺化合物及其制备方法和用途 |
| CN116307280B (zh) * | 2023-05-18 | 2023-08-01 | 成都理工大学 | 一种酸性气藏气井储层硫堵损伤量化评估方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2163060A1 (de) * | 1971-12-18 | 1973-06-20 | Basf Ag | Waesserige dispersionen von mischpolymerisaten von monoestern olefinisch ungesaettigter dicarbonsaeuren |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19839566C2 (de) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| RS52083B (sr) | 2001-01-12 | 2012-06-30 | Fumapharm Ag | Amidi fumarne kiseline |
| DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| DE10217314A1 (de) | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| GB0320441D0 (en) * | 2003-09-02 | 2003-10-01 | Givaudan Sa | Organic compounds |
| ATE380027T1 (de) | 2003-09-09 | 2007-12-15 | Fumapharm Ag | Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma |
| DE10342423A1 (de) | 2003-09-13 | 2005-04-14 | Heidland, August, Prof. Dr.med. Dr.h.c. | Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden |
| ES2525497T3 (es) | 2004-10-08 | 2015-10-09 | Forward Pharma A/S | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico |
| US20080004344A1 (en) | 2004-11-10 | 2008-01-03 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| DE102005022845A1 (de) | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
| CN101304732A (zh) * | 2005-10-07 | 2008-11-12 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
| US20080299196A1 (en) | 2005-10-07 | 2008-12-04 | Aditech Pharma Ab | Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester |
| MX2008014140A (es) | 2006-05-05 | 2009-01-19 | Univ Michigan | Mimeticos bivalentes de smac y los usos de los mismos. |
| RU2554347C2 (ru) * | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
| SG182414A1 (en) * | 2010-01-08 | 2012-08-30 | Catabasis Pharmaceuticals Inc | Fatty acid fumarate derivatives and their uses |
| US9868690B2 (en) | 2012-12-21 | 2018-01-16 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (MMF) |
-
2013
- 2013-02-07 BR BR112014019480A patent/BR112014019480A8/pt not_active IP Right Cessation
- 2013-02-07 US US13/761,864 patent/US8952006B2/en not_active Expired - Fee Related
- 2013-02-07 RU RU2014136394A patent/RU2014136394A/ru not_active Application Discontinuation
- 2013-02-07 WO PCT/US2013/025118 patent/WO2013119791A1/en not_active Ceased
- 2013-02-07 MX MX2014009511A patent/MX2014009511A/es unknown
- 2013-02-07 CN CN201380014174.7A patent/CN104169261A/zh active Pending
- 2013-02-07 NZ NZ629728A patent/NZ629728A/en not_active IP Right Cessation
- 2013-02-07 JP JP2014556656A patent/JP5918395B2/ja not_active Expired - Fee Related
- 2013-02-07 TW TW102104764A patent/TWI486339B/zh not_active IP Right Cessation
- 2013-02-07 CA CA2864040A patent/CA2864040A1/en not_active Abandoned
- 2013-02-07 EP EP13704701.5A patent/EP2812319A1/en not_active Withdrawn
- 2013-02-07 KR KR20147025151A patent/KR20140129136A/ko not_active Abandoned
- 2013-02-07 AU AU2013203335A patent/AU2013203335B2/en not_active Ceased
- 2013-08-14 US US13/967,283 patent/US20140051705A1/en not_active Abandoned
-
2014
- 2014-08-04 IL IL233941A patent/IL233941A0/en unknown
- 2014-08-21 ZA ZA2014/06145A patent/ZA201406145B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8952006B2 (en) | 2015-02-10 |
| BR112014019480A8 (pt) | 2017-07-11 |
| AU2013203335A1 (en) | 2013-08-22 |
| AU2013203335B2 (en) | 2016-05-26 |
| JP5918395B2 (ja) | 2016-05-18 |
| CA2864040A1 (en) | 2013-08-15 |
| NZ629728A (en) | 2016-07-29 |
| TW201343634A (zh) | 2013-11-01 |
| KR20140129136A (ko) | 2014-11-06 |
| TWI486339B (zh) | 2015-06-01 |
| CN104169261A (zh) | 2014-11-26 |
| RU2014136394A (ru) | 2016-03-27 |
| US20130203753A1 (en) | 2013-08-08 |
| WO2013119791A1 (en) | 2013-08-15 |
| US20140051705A1 (en) | 2014-02-20 |
| EP2812319A1 (en) | 2014-12-17 |
| MX2014009511A (es) | 2014-10-24 |
| IL233941A0 (en) | 2014-09-30 |
| JP2015508073A (ja) | 2015-03-16 |
| BR112014019480A2 (enExample) | 2017-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201406145B (en) | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use | |
| IL274988A (en) | Carbamoylpyridone-polycyclic compounds and their pharmaceutical use | |
| IL252566A0 (en) | Pharmacy preparations and methods | |
| IL234884A0 (en) | Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use | |
| EP2867209A4 (en) | COMPOUNDS AND THEIR THERAPEUTIC USES | |
| IL235831A0 (en) | A new dosage form and formulation of aveditrol | |
| IL234606A0 (en) | Innovative methods and compounds for the treatment of diseases | |
| IL235830A0 (en) | New dosage and formulation | |
| ZA201306905B (en) | Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these | |
| SI2938350T1 (sl) | Medicinska formulacija za zdravljenje hiperholesterolemije | |
| ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
| GB201208315D0 (en) | Pharmaceutical methods and compositions | |
| GB201216381D0 (en) | New compounds and medical uses | |
| GB201208970D0 (en) | New compounds and medical uses |